ClinicalTrials.Veeva

Menu

Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata (COLA)

P

Post Graduate Institute of Medical Education and Research, Chandigarh

Status and phase

Completed
Phase 4

Conditions

Alopecia Areata

Treatments

Drug: Topical latanoprost 0.005%
Drug: Topical betamethasone 0.05%

Study type

Interventional

Funder types

Other

Identifiers

NCT02350023
9121/PG-2Trg/12/8073

Details and patient eligibility

About

Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical corticosteroids are the established agents for treating this disorder. There are several case reports and case series which have demonstrated the efficacy of topical prostaglandins. The two agents have not been compared head-to-head in the published literature. The investigators attempt to compare the efficacy and safety of topical betamethasone and topical latanoprost in the treatment of localised alopecia areata.

Full description

Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical corticosteroids are the established agents for treating this disorder. Topical prostaglandins like latanoprost have also been used for this disorder. There are several case reports and case series which have demonstrated the efficacy of topical prostaglandins. However, the two agents i.e. topical corticosteroids and topical latanoprost have not been compared head-to-head in the published literature. The investigators attempt to compare the efficacy and safety of topical betamethasone and topical latanoprost in the treatment of localised alopecia areata.

Enrollment

50 patients

Sex

All

Ages

Under 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • • Cases of AA involving scalp and beard area, having 5 or less patches in all, involving less than 40% area

    • Stable disease without appearance of new patch or increase in size of existing patch for at least 15 days

Exclusion criteria

  • • Pregnant and lactating women

    • Patients on topical treatment for alopecia in the past fifteen days or on systemic treatment for alopecia in the past one month
    • Presence of any contraindication for topical corticosteroids (local skin infections, skin atrophy) or latanoprost (pregnancy, lactation and dermatitis)
    • Any other coexisting hair disorder (viz., trichotillomania, androgenetic alopecia, telogen effluvium)
    • Extensive disease i.e. >5 patches of AA or area involving >40% area / alopecia totalis/ alopecia universalis/ ophiasis

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

50 participants in 2 patient groups

Topical latanoprost
Active Comparator group
Description:
Topical latanoprost 0.005%
Treatment:
Drug: Topical latanoprost 0.005%
Topical betamethasone
Active Comparator group
Description:
Topical betamethasone 0.05%
Treatment:
Drug: Topical betamethasone 0.05%

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems